The new beta-lactamases.

By G. Jacoby, L. S. Munoz-Price. New England Journal of Medicine, 2005

720 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

CTX-M Enzymes: Origin and Diffusion (2012, background): “…ability to hydrolyze oxy-imino-cephalosporins (third and fourth generation cephalosporins) and monobactams but not cephamycins such as cefoxitin and carbapenems including imipenem, ertapenem, meropenem, or doripenem (Philippon et al., 1989; Jacoby and Muñoz-Price, 2005; Bush and Fisher, 2011).”
Action and resistance mechanisms of antibiotics: A guide for clinicians (2017, neutral): “, clavulanic acid, sulbactam, or tazobactam[21-23] b.”
Carbapenem Resistance: A Review (2017, background): “The clinical role of a fourth class (Ambler class C) is unknown but possesses some extended activity towards carbapenems [37,66].”
Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. (2011, background): “Resistance to broad-spectrum antimicrobials, such as the extended-spectrum cephalosporins, is a wellrecognized problem among Enterobacteriaceae [1].”
Acquired Antibiotic Resistance Genes: An Overview (2011, neutral): “…expressing β-lactamases, for example extended-spectrum β-lactamases (ESBLs), plasmid-mediated AmpC enzymes, and carbapenem-hydrolyzing β-lactamases (carbapenemases; Bradford, 2001; Jacoby and Munoz-Price, 2005; Paterson and Bonomo, 2005; Poirel et al., 2007; Queenan and Bush, 2007; Jacoby, 2009).”